AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie research and Development (R&D) Expense — GAAP ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Earnings
Latest, FY2025
9,096
Period ended Dec 31, 2025
Change on a year earlier
-28.9%
12,791 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Research and Development (R&D) Expense — GAAP ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9,096 | -28.9% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 12,791 | +66.7% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 7,675 | +17.9% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 6,510 | -6.0% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 6,922 | +8.5% | Form 10-K (filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | 6,379 | -0.4% | Form 10-K (filed 2023-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 6,407 | -38.0% | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 10,329 | +106.3% | Form 10-K (filed 2021-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 5,007 | +14.2% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 4,385 | +2.3% | Form 10-K (filed 2019-02-27) ↗ |
| FY2015 | Dec 31, 2015 | 4,285 | – | Form 10-K (filed 2018-02-16) ↗ |
Breakdown
What makes up research and development (r&d) expense — gaap ($m)
- Adjusted R&D Expense — Non-GAAP ($M)18 · FY2025
- Adjusted Investment in R&D — ESG Report ($B)13.80 · FY2025
- GAAP R&D Expense % of Net Revenues (%)–
- Adjusted R&D Expense % of Net Revenues — Non-GAAP (%)–
- New Product or Indication Approvals (approvals)6 · FY2025
- Programs Granted Expedited Regulatory Designations (programs)6 · FY2025
- FDA Breakthrough Therapy Designations (designations)1 · FY2025
- Compounds in Late-Stage Clinical Development with Novel Mechanism of Action (%)80.0% · FY2025
Cite this data
StockData. (2026). AbbVie Research and Development (R&D) Expense — GAAP ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rd_gaap_exp
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.